ClinicalTrials.gg
TerminatedNCT04645966Updated Mar 25, 2024Results posted

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

A Phase 2 interventional study of MenABCWY and Bivalent rLP2086 (60-µg Dose) in Meningococcal Vaccine, sponsored by Pfizer. Terminated at 21 sites in 3 countries. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Why this study was terminated
The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
2 Months to 6 Months
Sex
All
01

Study summary

The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.

02

Conditions studied

  • Meningococcal Vaccine

Keywords

  • Meningococcal Vaccine
  • Invasive Meningococcal Disease
  • Meningococcal Serogroups A, B, C W and Y
  • MenABCWY Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants, 2 months of age (≥60 to ≤98 days) or 6 months of age (≥150 to ≤210 days) at the time of randomization.
  2. Participant's parent(s)/legal guardian who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Participant is available for the entire study period and the participant's parent(s)/legal guardian can be reached by telephone.
  4. Healthy participant as determined by medical history, physical examination, and judgment of the investigator.
  5. Body weight ≥4 kg for participants 2 months of age at the time of randomization.
  6. Participants whose parent(s)/legal guardian are capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Prior adverse reaction to paracetamol use, including allergic reactions.
  2. Participant was born prematurely (\<37 weeks of gestation).
  3. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  5. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) therapy, or those receiving therapy. Please refer to the SRM for additional details.
  6. History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
  7. Significant neurological disorder or history of seizure (including simple febrile seizure).
  8. Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  9. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  10. Previous vaccination with any meningococcal vaccine. Written vaccination history must be obtained prior to randomization.
  11. For participants 2 months of age, prior vaccination with any of the following licensed or vaccines: pneumococcal vaccine and hexavalent DTPa--IPV-Hib or its component, except for the birth dose of hepatitis B vaccine.
  12. Participants receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  13. Receipt of any blood products, including immunoglobulin, before the first study vaccination.
  14. Current chronic use of systemic antibiotics.
  15. Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 28 days prior to study entry and/or during study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Care provider, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    MenABCWY with PLP - 6 months of age

    Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.

    Biological: MenABCWY · Drug: Prophylactic Liquid Paracetamol (PLP)

  • Experimental
    MenABCWY - 6 months of age

    Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule

    Biological: MenABCWY

  • Experimental
    Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age

    Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Pracetamol (SLP) during primary vaccinations.

    Biological: Bivalent rLP2086 (60-µg Dose) · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix · Drug: Scheduled Liquid Paracetamol (SLP)

  • Experimental
    Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age

    Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule

    Biological: Bivalent rLP2086 (60-µg Dose) · Biological: Nimenrix

  • Experimental
    Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age

    Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.

    Biological: Bivalent rLP2086 (120-µg Dose) · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix

  • Experimental
    MenABCWY with SLP - 2 months of age

    Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.

    Biological: MenABCWY · Drug: Scheduled Liquid Paracetamol (SLP)

  • Experimental
    Bexsero and Nimenrix with PLP - 2 months of age

    Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations

    Biological: Bexsero · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix

  • Experimental
    Bexsero and Nimenrix - 2 months of age

    Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule

    Biological: Bexsero · Biological: Nimenrix

  • Experimental
    MenABCWY with TLP - 2 months of age

    Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.

    Biological: MenABCWY · Drug: Therapeutic Liquid Paracetamol (TLP)

  • Experimental
    Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age

    Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.

    Biological: MenABCWY · Other: Placebo · Drug: Scheduled Liquid Paracetamol (SLP) · Drug: Therapeutic Liquid Paracetamol (TLP)

  • Experimental
    Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age

    Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.

    Biological: Bexsero · Drug: Prophylactic Liquid Paracetamol (PLP) · Biological: Nimenrix · Drug: Therapeutic Liquid Paracetamol (TLP)

Interventions

  • BiologicalMenABCWY

    Neisseria meningitis groups A, B, C W, and Y vaccine

  • BiologicalBivalent rLP2086 (60-µg Dose)

    Trumenba (half dose) - Meningococcal Group B vaccine

  • BiologicalBivalent rLP2086 (120-µg Dose)

    Trumenba - Meningococcal Group B vaccine

  • BiologicalBexsero

    Bexsero - Meningococcal Group B vaccine

  • DrugProphylactic Liquid Paracetamol (PLP)

    PLP administration during primary vaccinations 1 and 2

  • BiologicalNimenrix

    Nimenrix - Meningococcal Group A, C, W and Y vaccine

  • OtherPlacebo

    Normal Saline

  • DrugScheduled Liquid Paracetamol (SLP)

    SLP administration after primary vaccinations 1 and 2.

  • DrugTherapeutic Liquid Paracetamol (TLP)

    TLP administration after primary vaccinations 1 and 2

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=LLOQ for Each MenA, MenC, MenW and MenY Test Strains 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Percentage of participants achieving hSBA titer greater than or equal to (\>=) lower limit of quantitation (LLOQ) (i.e.,1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided confidence interval (CI) using the Clopper and Pearson method was presented. Analysis was performed on Post-primary vaccination 2 (post-PV2) evaluable immunogenicity population (EIP). No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.

    Time frame: 1 month after primary vaccination 2

  2. Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenACWY MenA, MenC, MenW and MenY Test Strains 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Percentage of participants achieving hSBA titer \>= LLOQ (1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.

    Time frame: 1 month after booster vaccination

  3. Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.

    Time frame: 1 month After primary vaccination 2

  4. Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 3 and 4 Combined Versus Group 5

    Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain(1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented.

    Time frame: 1 month after primary vaccination 2

  5. Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.

    Time frame: 1 Month after booster vaccination

  6. Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Groups 3, 4 and 5

    Percentage of participants achieving hSBA titer \>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. Groups 4 and 5 had no serum samples collected post-booster for serology testing due to study termination.

    Time frame: 1 Month after booster vaccination

  7. Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after primary vaccination 1

  8. Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

    Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 Days after primary Vaccination 2

  9. Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method

    Time frame: Within 7 Days after primary Vaccination 1

  10. Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

    Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness was graded as Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after primary vaccination 2

  11. Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Medically attended adverse event (MAE) was defined as a nonserious AE that resulted in an evaluation at a medical facility. Newly diagnosed chronic medical condition (NDCMC) was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Within 30 days after primary vaccination 1

  12. Percentage of Participants With AEs, SAEs,MAEs and NDCMC Within 30 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that wasis expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Within 30 days after primary vaccination 2

  13. Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Any Primary Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that is was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Within 30 days after any primary vaccination

  14. Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Primary Series Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From day of primary vaccination 1 at Day 1 up to 1 month after primary vaccination 2

  15. Percentage of Participants With SAEs, MAEs and NDCMC During Primary Series Follow-up Phase: Group 7 Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month after primary vaccination 2 up to booster vaccination

  16. Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Primary Series Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.

    Time frame: From the date of primary vaccination 1 up to 8 months after primary vaccination 2 (maximum up to 9 months)

  17. Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined

    Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

    Time frame: Within 30 minutes After primary vaccination 1

  18. Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined

    Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

    Time frame: Within 30 minutes After primary vaccination 2

  19. Percentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

    Time frame: Within 30 minutes after booster vaccination

  20. Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement.

    Time frame: Within 7 Days after booster vaccination

  21. Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C, categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was graded as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after booster vaccination

  22. Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From date of booster vaccination through 1 month after booster vaccination

  23. Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Follow-up Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 5 months)

  24. Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Booster Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 6 months)

Secondary outcomes

  1. hSBA Geometric Mean Titers (GMTs) for Each of the MenB Test Strains: 1 Month After Primary Vaccination 2 in Group 3 and 4 Combined Versus Group 5

    GMTs were calculated by exponentiating mean logarithm of titers and CIs were calculated by exponentiating confidence limits based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 Month after primary Vaccination 2

  2. hSBA GMTs for Each of the MenB Test Strains: 1 Month After Booster Vaccination in Groups 3, 4 and 5

    GMTs were calculated by exponentiating the mean logarithm of the titers and CIs were calculated by exponentiating the confidence limits based on the Student t distribution for the mean logarithm of the titers. No serum samples were collected after booster dose for groups 4 and 5 due to study termination.

    Time frame: 1 month after booster vaccination

  3. Percentage of Participants With Local Reactions Within 7 Days After Each Primary Vaccination: Group 3, 4 and 5

    Local reactions included pain at injection site, redness and swelling and were recorded by participant's in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site on left arm were reported in this outcome measure.

    Time frame: Within 7 Days after primary Vaccination(Vac) 1 and 2

  4. Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Each Primary Vaccination: Group 3,4 and 5

    Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Exact 2-sided CI was based on the Clopper and Pearson method. Decreased appetite was categorized as Grade 1:decreased interest in eating, Grade 2:decreased oral intake, Grade3: refusal to feed. Drowsiness: Grade 1 Increased or prolonged sleeping bouts,Grade2: Slightly subdued interfering with daily activity, Grade3; Disabling, not interested in usual daily activity. Irritability; Grade1: Easily consolable, Grade2: requiring increased attention, Grade 3: Inconsolable; crying could not be comforted.

    Time frame: Within 7 Days after primary Vaccination 1 and 2

  5. Percentage of Participants With AEs, SAEs, MAEs and NDCMC: Groups 3, 4 and 5

    Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.

    Time frame: Within 30 days after any vaccination

07

Results

Posted Mar 25, 2024
Limitations and caveats
Study was terminated based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.

Participant flow

Vaccination Phase
Participant flow — Vaccination Phase
MilestoneGroup 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)
Started232536165350555512
Primary vaccination 1232539165050555512
Primary vaccination 222252316504254550
Booster vaccination22252249047450
Completed22252002025220
Not completed1016165150303312
Withdrew: Adverse event100000100
Withdrew: Death000001000
Withdrew: Protocol violation000010000
Withdrew: Study terminated by sponsor0014154743292912
Withdrew: Withdrawal by parent/guardian002134020
Withdrew: Other000002000
Withdrew: Lost to follow-up000000010
Withdrew: No longer meets eligibility criteria000000010
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneGroup 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)
Started22252002025220
Completed22252002025210
Not completed000000010
Withdrew: Lost to follow-up000000010

Outcome measures

PrimaryPercentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=LLOQ for Each MenA, MenC, MenW and MenY Test Strains 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Percentage of participants achieving hSBA titer greater than or equal to (\>=) lower limit of quantitation (LLOQ) (i.e.,1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided confidence interval (CI) using the Clopper and Pearson method was presented. Analysis was performed on Post-primary vaccination 2 (post-PV2) evaluable immunogenicity population (EIP). No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.

Time frame:
1 month after primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=LLOQ for Each MenA, MenC, MenW and MenY Test Strains 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
MenA100.0 (79.4 to 100.0)100.0 (96.0 to 100.0)
MenC100.0 (79.4 to 100.0)100.0 (96.0 to 100.0)
MenW100.0 (79.4 to 100.0)100.0 (96.0 to 100.0)
MenY100.0 (79.4 to 100.0)100.0 (96.1 to 100.0)
PrimaryPercentage of Participants Achieving hSBA Titer >= LLOQ for Each MenACWY MenA, MenC, MenW and MenY Test Strains 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Percentage of participants achieving hSBA titer \>= LLOQ (1:8) for each MenA, MenC, MenW and MenY test strains were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.

Time frame:
1 month after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenACWY MenA, MenC, MenW and MenY Test Strains 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
MenA—100.0 (91.4 to 100.0)
MenC—100.0 (91.4 to 100.0)
MenW—100.0 (91.6 to 100.0)
MenY—100.0 (91.4 to 100.0)
PrimaryPercentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No serum samples collected after vaccination 2 for participants in Group 11 as participants were not administered PV 2 due to study termination.

Time frame:
1 month After primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
PMB80 (A22)44.4 (21.5 to 69.2)9.6 (4.5 to 17.4)
PMB2707 (B44)88.9 (65.3 to 98.6)29.5 (20.6 to 39.7)
PrimaryPercentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 3 and 4 Combined Versus Group 5

Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain(1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented.

Time frame:
1 month after primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each Neisseria Meningitidis Group B (MenB) Test Strain 1 Month After Primary Vaccination 2: Group 3 and 4 Combined Versus Group 5
Percentage of participantsGroup 3 and 4 CombinedGroup 5 (120 mcg rLP2086 +Nimenrix +PLP)
PMB80 (A22)46.7 (28.3 to 65.7)47.7 (32.5 to 63.3)
PMB2707 (B44)82.9 (66.4 to 93.4)97.8 (88.2 to 99.9)
PrimaryPercentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Percentage of participants achieving hSBA titer\>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. No participants in Group 7 and Group 11 received booster vaccination due to study termination.

Time frame:
1 Month after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
PMB80 (A22)—25.0 (12.7 to 41.2)
PMB2707 (B44)—34.1 (20.1 to 50.6)
PrimaryPercentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Groups 3, 4 and 5

Percentage of participants achieving hSBA titer \>= LLOQ for each MenB test strain (1:16 for strain A22 and 1:8 for strain B44) is reported in this outcome measure. Exact 2-sided CI using Clopper and Pearson method is presented. Groups 4 and 5 had no serum samples collected post-booster for serology testing due to study termination.

Time frame:
1 Month after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer >= LLOQ for Each MenB Test Strain 1 Month After Booster Vaccination: Groups 3, 4 and 5
Percentage of participantsGroup 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)
PMB80 (A22)38.9 (17.3 to 64.3)——
PMB2707 (B44)83.3 (58.6 to 96.4)——
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after primary vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Redness: Mild22.6 (12.9 to 35.0)23.1 (15.6 to 32.2)
Redness: Moderate11.3 (4.7 to 21.9)6.5 (2.6 to 12.9)
Redness: Severe0 (0.0 to 5.8)0 (0.0 to 3.4)
Swelling: Mild21.0 (11.7 to 33.2)22.2 (14.8 to 31.2)
Swelling: Moderate17.7 (9.2 to 29.5)12.0 (6.6 to 19.7)
Swelling: Severe0 (0.0 to 5.8)0 (0.0 to 3.4)
Tenderness at injection site: Mild22.6 (12.9 to 35.0)25.9 (18.0 to 35.2)
Tenderness at injection site: Moderate48.4 (35.5 to 61.4)24.1 (16.4 to 33.3)
Tenderness at injection site: Severe0 (0.0 to 5.8)0.9 (0.0 to 5.1)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 Days after primary Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
Percentage of participantsGroup 7Group 8 and 10 Combined
Redness: Mild26.8 (14.2 to 42.9)27.1 (19.0 to 36.6)
Redness: Moderate12.2 (4.1 to 26.2)11.2 (5.9 to 18.8)
Redness: Severe0 (0.0 to 8.6)0 (0.0 to 3.4)
Swelling: Mild19.5 (8.8 to 34.9)25.2 (17.3 to 34.6)
Swelling: Moderate14.6 (5.6 to 29.2)12.1 (6.6 to 19.9)
Swelling: Severe0 (0.0 to 8.6)0 (0.0 to 3.4)
Tenderness at injection site: Mild22.0 (10.6 to 37.6)27.1 (19.0 to 36.6)
Tenderness at injection site: Moderate34.1 (20.1 to 50.6)23.4 (15.7 to 32.5)
Tenderness at injection site: Severe4.9 (0.6 to 16.5)2.8 (0.6 to 8.0)
PrimaryPercentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method

Time frame:
Within 7 Days after primary Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Fever: 38.0°C to 38.4°C29.0 (18.2 to 41.9)15.7 (9.4 to 24.0)
Fever: >38.4°C to 38.9°C24.2 (14.2 to 36.7)5.6 (2.1 to 11.7)
Fever: >38.9°C to 40.0°C9.7 (3.6 to 19.9)0 (0.0 to 3.4)
Fever: >40.0°C0 (0.0 to 5.8)0 (0.0 to 3.4)
Decreased appetite: Mild17.7 (9.2 to 29.5)17.6 (10.9 to 26.1)
Decreased appetite: Moderate43.5 (31.0 to 56.7)21.3 (14.0 to 30.2)
Decreased appetite: Severe4.8 (1.0 to 13.5)0.9 (0.0 to 5.1)
Irritability: Mild21.0 (11.7 to 33.2)19.4 (12.5 to 28.2)
Irritability: Moderate59.7 (46.4 to 71.9)45.4 (35.8 to 55.2)
Irritability: Severe14.5 (6.9 to 25.8)6.5 (2.6 to 12.9)
Drowsiness: Mild37.1 (25.2 to 50.3)39.8 (30.5 to 49.7)
Drowsiness: Moderate32.3 (20.9 to 45.3)18.5 (11.7 to 27.1)
Drowsiness: Severe4.8 (1.0 to 13.5)0.9 (0.00 to 5.1)
Use of antipyretic medication46.8 (34.0 to 59.9)50.0 (40.2 to 59.8)
PrimaryPercentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was categorized as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness was graded as Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
Percentage of participantsGroup 7Group 8 and 10 Combined
Fever: 38.0°C to 38.4°C26.8 (14.2 to 42.9)31.8 (23.1 to 41.5)
Fever: >38.4°C to 38.9°C26.8 (14.2 to 42.9)14.0 (8.1 to 22.1)
Fever: >38.9°C to 40.0°C12.2 (4.1 to 26.2)2.8 (0.6 to 8.0)
Fever: >40.0°C0 (0.0 to 8.6)0 (0.0 to 3.4)
Decreased appetite: Mild22.0 (10.6 to 37.6)20.6 (13.4 to 29.5)
Decreased appetite: Moderate31.7 (18.1 to 48.1)25.2 (17.3 to 34.6)
Decreased appetite: Severe4.9 (0.6 to 16.5)3.7 (1.0 to 9.3)
Irritability: Mild12.2 (4.1 to 26.2)21.5 (14.1 to 30.5)
Irritability: Moderate53.7 (37.4 to 69.3)48.6 (38.8 to 58.5)
Irritability: Severe22.0 (10.6 to 37.6)6.5 (2.7 to 13.0)
Drowsiness: Mild29.3 (16.1 to 45.5)45.8 (36.1 to 55.7)
Drowsiness: Moderate34.1 (20.1 to 50.6)14.0 (8.1 to 22.1)
Drowsiness: Severe4.9 (0.6 to 16.5)0.9 (0.0 to 5.1)
Use of antipyretic medication41.5 (26.3 to 57.9)72.9 (63.4 to 81.0)
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Medically attended adverse event (MAE) was defined as a nonserious AE that resulted in an evaluation at a medical facility. Newly diagnosed chronic medical condition (NDCMC) was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Within 30 days after primary vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Primary Vaccination 1: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs24.216.4
SAEs4.80
MAEs14.510.0
NDCMCs00.9
PrimaryPercentage of Participants With AEs, SAEs,MAEs and NDCMC Within 30 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that wasis expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Within 30 days after primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs,MAEs and NDCMC Within 30 Days After Primary Vaccination 2: Group 7 Versus Group 8 and 10 Combined
Percentage of participantsGroup 7Group 8 and 10 Combined
AEs33.312.8
SAEs2.40
MAEs23.811.0
NDCMC00.9
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Any Primary Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that is was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Within 30 days after any primary vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Within 30 Days After Any Primary Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs40.324.5
SAEs6.50
MAEs29.016.4
NDCMC00.9
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC During Primary Series Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From day of primary vaccination 1 at Day 1 up to 1 month after primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Primary Series Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs56.533.6
SAEs6.51.8
MAEs43.524.5
NDCMC1.60.9
PrimaryPercentage of Participants With SAEs, MAEs and NDCMC During Primary Series Follow-up Phase: Group 7 Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month after primary vaccination 2 up to booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs, MAEs and NDCMC During Primary Series Follow-up Phase: Group 7 Versus Group 8 and 10 Combined
Percentage of participantsGroup 7Group 8 and 10 Combined
AEs17.118.3
SAEs4.92.8
MAEs12.215.6
NDCMC00.9
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Primary Series Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.

Time frame:
From the date of primary vaccination 1 up to 8 months after primary vaccination 2 (maximum up to 9 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Primary Series Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs59.740.0
SAEs9.74.5
MAEs45.230.0
NDCMC1.61.8
PrimaryPercentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined

Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

Time frame:
Within 30 minutes After primary vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 1: Groups 7 and 11 Combined Versus Groups 8 and 10 Combined00
PrimaryPercentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined

Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

Time frame:
Within 30 minutes After primary vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined
Percentage of participantsGroup 7Group 8 and 10 Combined
Percentage of Participants With Immediate AEs Within 30 Minutes After Primary Vaccination 2: Group 7 Versus Groups 8 and 10 Combined00
PrimaryPercentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration.

Time frame:
Within 30 minutes after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Percentage of Participants With Immediate AEs After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined—0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Local reactions included tenderness at injection site, redness and swelling and were recorded by participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: 0.5 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Tenderness at injection site was graded as mild: hurt if gently touched, moderate: hurt if gently touched with crying and severe: caused limitation of limb movement.

Time frame:
Within 7 Days after booster vaccination
Reported as:
Number · Participants
Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
ParticipantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Redness—38
Swelling—35
Tenderness at injection site—63
PrimaryPercentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined

Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 deg C, categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite was graded as Mild: decreased interest in eating, Moderate: decreased oral intake, Severe: refusal to feed. Drowsiness: Mild: Increased or prolonged sleeping bouts, Moderate: Slightly subdued interfering with daily activity, Severe; Disabling, not interested in usual daily activity. Irritability; Mild: Easily consolable, Moderate: required increased attention, Severe: Inconsolable; crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
Fever: 38.0°C to 38.4°C—19.8 (12.2 to 29.4)
Fever: >38.4°C to 38.9°C—11.0 (5.4 to 19.3)
Fever: >38.9°C to 40.0°C—4.4 (1.2 to 10.9)
Fever: >40.0°C—0 (0.0 to 4.0)
Decreased appetite: Mild—17.6 (10.4 to 27.0)
Decreased appetite: Moderate—27.5 (18.6 to 37.8)
Decreased appetite: Severe—2.2 (0.3 to 7.7)
Irritability: Mild—22.0 (14.0 to 31.9)
Irritability: Moderate—42.9 (32.5 to 53.7)
Irritability: Severe—7.7 (3.1 to 15.2)
Drowsiness: Mild—26.4 (17.7 to 36.7)
Drowsiness: Moderate—18.7 (11.3 to 28.2)
Drowsiness: Severe—1.1 (0.0 to 6.0)
Use of antipyretic medication—63.7 (53.0 to 73.6)
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From date of booster vaccination through 1 month after booster vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Vaccination Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs—27.2
SAEs—0
MAEs—92
NDCMC—0
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Follow-up Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 5 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC During Booster Follow-up Phase: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs—17.4
SAEs—2.2
MAEs—15.2
NDCMC—0
PrimaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Booster Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. MAE was defined as a nonserious AE that resulted in an evaluation at a medical facility. NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month after booster vaccination up to 6 months after booster vaccination (maximum up to 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC Throughout Booster Stage: Group 7 and 11 Combined Versus Group 8 and 10 Combined
Percentage of participantsGroup 7 and 11 CombinedGroup 8 and 10 Combined
AEs—40.2
SAEs—2.2
MAEs—25.0
NDCMC—0
SecondaryhSBA Geometric Mean Titers (GMTs) for Each of the MenB Test Strains: 1 Month After Primary Vaccination 2 in Group 3 and 4 Combined Versus Group 5

GMTs were calculated by exponentiating mean logarithm of titers and CIs were calculated by exponentiating confidence limits based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 Month after primary Vaccination 2
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers (GMTs) for Each of the MenB Test Strains: 1 Month After Primary Vaccination 2 in Group 3 and 4 Combined Versus Group 5
TitersGroup 3 and 4 CombinedGroup 5 (120 mcg rLP2086 +Nimenrix +PLP)
PMB80 (A22)13.9 (10.8 to 18.0)15.3 (12.1 to 19.3)
PMB2707 (B44)25.0 (19.9 to 31.4)25.0 (19.9 to 31.4)
SecondaryhSBA GMTs for Each of the MenB Test Strains: 1 Month After Booster Vaccination in Groups 3, 4 and 5

GMTs were calculated by exponentiating the mean logarithm of the titers and CIs were calculated by exponentiating the confidence limits based on the Student t distribution for the mean logarithm of the titers. No serum samples were collected after booster dose for groups 4 and 5 due to study termination.

Time frame:
1 month after booster vaccination
Reported as:
Geometric mean · Titers
hSBA GMTs for Each of the MenB Test Strains: 1 Month After Booster Vaccination in Groups 3, 4 and 5
TitersGroup 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)
PMB80 (A22)21.8 ± 11.1——
PMB2707 (B44)25.4 ± 12.6——
SecondaryPercentage of Participants With Local Reactions Within 7 Days After Each Primary Vaccination: Group 3, 4 and 5

Local reactions included pain at injection site, redness and swelling and were recorded by participant's in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site on left arm were reported in this outcome measure.

Time frame:
Within 7 Days after primary Vaccination(Vac) 1 and 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Each Primary Vaccination: Group 3, 4 and 5
Percentage of participantsGroup 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)
Vaccination 1:Redness:Mild27.8 (14.2 to 45.2)18.8 (4.0 to 45.6)13.2 (5.5 to 25.3)
Vacc1Redness:Moderate8.3 (1.8 to 22.5)0 (0.0 to 20.6)3.8 (0.5 to 13.0)
Vacc1Redness: Severe0 (0.0 to 9.7)0 (0.0 to 20.6)0 (0.0 to 6.7)
Vacc1:Swelling: Mild16.7 (6.4 to 32.8)6.3 (0.2 to 30.2)9.4 (3.1 to 20.7)
Vacc1:Swelling: Moderate11.1 (3.1 to 26.1)12.5 (1.6 to 38.3)5.7 (1.2 to 15.7)
Vacc1:Swelling: Severe0 (0. to 9.7)0 (0.0 to 20.6)0 (0.0 to 6.7)
Vac1Tenderness at inj.site:Mild19.4 (8.2 to 36.0)12.5 (1.6 to 38.3)22.6 (12.3 to 36.2)
Vac1Tenderness at inj.site: Moderate41.7 (25.5 to 59.2)18.8 (4.0 to 45.6)20.8 (10.8 to 34.1)
Vac1Tenderness at inj.site: Severe0 (0.0 to 9.7)0 (0.0 to 20.6)1.9 (0.0 to 10.1)
Vac2Redness: Mild33.3 (14.6 to 57.0)18.8 (4.0 to 45.6)19.2 (9.6 to 32.5)
Vac2Redness: Moderate4.8 (0.1 to 23.8)0 (0.0 to 20.6)3.8 (0.5 to 13.2)
Vac2Redness: Severe0 (0.0 to 16.1)0 (0.0 to 20.6)0 (0.0 to 6.8)
Vac2Swelling: Mild19.0 (5.4 to 41.9)12.5 (1.6 to 38.3)9.6 (3.2 to 21.0)
Vac2Swelling: Moderate0 (0.0 to 16.1)12.5 (1.6 to 38.3)1.9 (0.0 to 10.3)
Vac2Swelling Severe0 (0.0 to 16.1)0 (0.0 to 20.6)0 (0.0 to 6.8)
Vac2Tenderness at inj.site Mild28.6 (11.3 to 52.2)12.5 (1.6 to 38.3)32.7 (20.3 to 47.1)
Vac2Tenderness at inj.siteModerate9.5 (1.2 to 30.4)18.8 (4.0 to 45.6)17.3 (8.2 to 30.3)
Vac2Tenderness at inj.siteSevere0 (0.0 to 16.1)6.3 (0.2 to 30.2)1.9 (0.0 to 10.3)
SecondaryPercentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Each Primary Vaccination: Group 3,4 and 5

Systemic events were recorded by participant's parents/legal guardians in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius(C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Exact 2-sided CI was based on the Clopper and Pearson method. Decreased appetite was categorized as Grade 1:decreased interest in eating, Grade 2:decreased oral intake, Grade3: refusal to feed. Drowsiness: Grade 1 Increased or prolonged sleeping bouts,Grade2: Slightly subdued interfering with daily activity, Grade3; Disabling, not interested in usual daily activity. Irritability; Grade1: Easily consolable, Grade2: requiring increased attention, Grade 3: Inconsolable; crying could not be comforted.

Time frame:
Within 7 Days after primary Vaccination 1 and 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events and Antipyretic Use Within 7 Days After Each Primary Vaccination: Group 3,4 and 5
Percentage of participantsGroup 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)
Vac1Fever38.0°C to 38.4°C30.6 (16.3 to 48.1)18.8 (4.0 to 45.6)35.8 (23.1 to 50.2)
Vac1Fever>38.4°C to 38.9°C27.8 (14.2 to 45.2)6.3 (0.2 to 30.2)17.0 (8.1 to 29.8)
Vac1Fever>38.9°C to 40.0°C0 (0.0 to 9.7)0 (0.0 to 20.6)11.3 (4.3 to 23.0)
Vac1Fever >40.0°C0 (0.0 to 9.7)0 (0.0 to 20.6)0 (0.0 to 6.7)
Vac1Decreased appetite Mild25.0 (12.1 to 42.2)6.3 (0.2 to 30.2)28.3 (16.8 to 42.3)
Vac1Decreased appetite Moderate22.2 (10.1 to 39.2)43.8 (19.8 to 70.1)34.0 (21.5 to 48.3)
Vac1Decreasedappetite Severe2.8 (0.1 to 14.5)0 (0.0 to 20.6)3.8 (0.5 to 13.0)
Vac1IrritabilityMild16.7 (6.4 to 32.8)6.3 (0.2 to 30.2)5.7 (1.2 to 15.7)
Vac1IrritabilityModerate58.3 (40.8 to 74.5)75.0 (47.6 to 92.7)58.5 (44.1 to 71.9)
Vac1IrritabilitySevere8.3 (1.8 to 22.5)6.3 (0.22 to 30.2)13.2 (5.5 to 25.3)
Vac1DrowsinessMild36.1 (20.8 to 53.8)37.5 (15.2 to 64.6)49.1 (35.1 to 63.2)
Vac1DrowsinessModerate33.3 (18.6 to 51.0)31.3 (11.0 to 58.7)39.6 (26.5 to 54.0)
Vac1DrowsinessSevere2.8 (0.1 to 14.5)0 (0.0 to 20.6)3.8 (0.5 to 13.0)
Use of antipyretic medication58.3 (40.8 to 74.5)56.3 (29.9 to 80.2)83.0 (70.2 to 91.9)
Vac2 >38.0°C to 38.4°C23.8 (8.2 to 47.2)25.0 (7.3 to 52.4)28.8 (17.1 to 43.1)
Vac2 >>38.4°C to 38.9°C23.8 (8.2 to 47.2)25.0 (7.3 to 52.4)25.0 (14.0 to 38.9)
Vac2>>38.9°C to 40.0°C4.8 (0.1 to 23.8)0 (0.0 to 20.6)13.5 (5.6 to 25.8)
Vac2>40.0°C0 (0.0 to 16.1)0 (0.0 to 20.6)0 (0.0 to 6.8)
Vac2Decreased appetiteMild4.8 (0.1 to 23.8)6.3 (0.2 to 30.2)28.8 (17.1 to 43.1)
Vac2Decreased appetiteModerate28.6 (11.3 to 52.2)50.0 (24.7 to 75.3)38.5 (25.3 to 53.0)
Vac2Decreased appetite Severe4.8 (0.1 to 23.8)6.3 (0.2 to 30.2)5.8 (1.2 to 15.9)
Vac2 Irritability Mild28.6 (11.3 to 52.2)12.5 (1.6 to 38.3)21.2 (11.1 to 34.7)
Vac2IrritabilityModerate23.8 (8.2 to 47.2)68.8 (41.3 to 89.0)48.1 (34.0 to 62.4)
Vac2IrritabilitySevere4.8 (0.1 to 23.8)0 (0.0 to 20.6)9.6 (3.2 to 21.0)
Vac2DrowsinessMild47.6 (25.7 to 70.2)43.8 (19.8 to 70.1)40.4 (27.0 to 54.9)
Vac2DrowsinessModertae23.8 (8.2 to 47.2)12.5 (1.6 to 38.3)28.8 (17.1 to 43.1)
Vac2DrowsinessSevere0 (0.0 to 16.1)0 (0.0 to 20.6)3.8 (0.5 to 13.2)
Vac2Use of antipyretic medication81.0 (58.1 to 94.6)87.5 (61.7 to 98.4)86.5 (74.2 to 94.4)
SecondaryPercentage of Participants With AEs, SAEs, MAEs and NDCMC: Groups 3, 4 and 5

Infant participants aged 2 months were administered single IM injection of 0.5mL of Bexsero into left thigh, 0.5mL of Nimenrix into right thigh at Day 1(primary vaccination 1), Month 2 (primary vaccination 2) and approximately 10 months after vaccination 1 (booster vaccination). Participants in Group 8 were administered PLP orally with 3 required doses, first dose starting 30 minutes before vaccination at Day1 and Month 2. All participants received single IM injection of Prevenar 13 and Vaxelis into right thigh at 2 and 4 months of age.

Time frame:
Within 30 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs, SAEs, MAEs and NDCMC: Groups 3, 4 and 5
Percentage of participantsGroup 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)
AEs52.868.860.4
SAEs2.86.320.8
MAEs47.262.547.2
NDCMC06.30

Adverse events

Collected over Systematic assessment(SA): local reactions/systemic events within 7 days after vaccination 1, 2 and booster vaccination; Non-systematic assessment: SAEs and other AEs from Day 1 up to 196 days after last study vaccination (up to 12 months for Group1 and 2; up to 16 months for Group 3,4,5,7,8,10,11). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (MenABCWY +PLP)0/23 (0%)0/23 (0%)23/23 (100%)
Group 2 (MenABCWY)0/25 (0%)1/25 (4%)25/25 (100%)
Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)0/36 (0%)1/36 (2.8%)36/36 (100%)
Group 4 (60 mcg rLP2086 +Nimenrix)0/16 (0%)1/16 (6.3%)16/16 (100%)
Group 5 (120 mcg rLP2086 +Nimenrix +PLP)0/53 (0%)11/53 (20.8%)53/53 (100%)
Group 7 (MenABCWY +SLP)1/50 (2%)5/50 (10%)50/50 (100%)
Group 8 (Bexsero +Nimenrix +PLP)0/55 (0%)1/55 (1.8%)54/55 (98.2%)
Group 10 (Bexsero +Nimenrix)0/55 (0%)6/55 (10.9%)55/55 (100%)
Group 11 (MenABCWY +TLP)0/12 (0%)1/12 (8.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGroup 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)
Meningitis bacterialInfections and infestations0/230/250/360/160/530/500/550/551/12
BronchiolitisInfections and infestations0/230/250/361/162/532/500/550/550/12
PapilloedemaEye disorders0/231/250/360/160/530/500/550/550/12
BronchospasmRespiratory, thoracic and mediastinal disorders0/230/250/360/162/531/500/550/550/12
Respiratory syncytial virus bronchiolitisInfections and infestations0/230/250/360/160/530/501/552/550/12
LymphadenitisBlood and lymphatic system disorders0/230/251/360/160/530/500/550/550/12
Sudden infant death syndromeGeneral disorders0/230/250/360/160/531/500/550/550/12
Escherichia urinary tract infectionInfections and infestations0/230/250/360/160/531/500/550/550/12
DiarrhoeaGastrointestinal disorders0/230/250/360/161/530/500/550/550/12
COVID-19Infections and infestations0/230/250/360/161/530/500/551/550/12
Most frequent other events
Showing 10 of 126
Most frequent other events
EventGroup 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)
Irritability (IRRITABILITY)Psychiatric disorders22/2320/2532/3614/1650/5349/5044/5549/5512/12
Hypersomnia (INCREASED SLEEP)Nervous system disorders18/2318/2532/3612/1650/5339/5044/5543/5510/12
Tenderness (TENDERNESS)General disorders20/2320/2523/368/1635/5341/5041/5545/558/12
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders18/2317/2525/3611/1646/5338/5037/5541/559/12
Pyrexia (FEVER)General disorders15/2319/2525/3610/1642/5338/5032/5539/557/12
Erythema (REDNESS)Skin and subcutaneous tissue disorders8/2313/2518/366/1619/5322/5031/5535/554/12
Swelling (SWELLING)General disorders10/2314/2513/365/1610/5326/5030/5531/552/12
GastroenteritisInfections and infestations6/238/252/360/161/531/504/554/550/12
Hand-foot-and-mouth diseaseInfections and infestations0/237/250/360/160/530/503/550/550/12
PyrexiaGeneral disorders6/232/252/360/164/534/503/555/550/12

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination.

Age, Continuous
Age, Continuous(Days)Group 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)Total
Mean158.5 ± 6.87161.6 ± 14.4571.1 ± 7.0067.6 ± 5.8168.9 ± 6.3968.0 ± 5.9967.4 ± 7.8967.5 ± 7.3069.4 ± 7.6981.9 ± 33.51
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)Total
Female1210217242732207160
Male1115159292323355165
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)Total
Hispanic or Latino139218102518226132
Not Hispanic or Latino1016158432537336193
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (MenABCWY +PLP)Group 2 (MenABCWY)Group 3 (60 mcg rLP2086 +Nimenrix +PLP/SLP)Group 4 (60 mcg rLP2086 +Nimenrix)Group 5 (120 mcg rLP2086 +Nimenrix +PLP)Group 7 (MenABCWY +SLP)Group 8 (Bexsero +Nimenrix +PLP)Group 10 (Bexsero +Nimenrix)Group 11 (MenABCWY +TLP)Total
American Indian or Alaska Native0000000000
Asian0000000000
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1110000003
White202435165250555512319
More than one race0000000000
Unknown or Not Reported2000100003
08

Study locations

21 sites
  • Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche
    Mannheim, 68161, Germany
  • P. & A. Kyriakou Children's Hospital
    Athens, 11527, Greece
  • University General Hospital "ATTIKON"
    Athens, 12462, Greece
  • "Ippokratio" General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • Hospital Clinico Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario de Burgos
    Burgos, Castilla Y LEON 09006, Spain
  • Hospital Universitario HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
  • Centro de Salud L'Eliana
    L'Eliana, Valencia 46183, Spain
  • Centro de Salud de Paiporta
    Paiporta, Valencia 46200, Spain
  • Hospital Vithas Virgen del Mar
    Almeria, 04120, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28009, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Grupo Pediatrico Uncibay
    Malaga, 29015, Spain
  • Instituto Hispalense de Pediatria
    Sevilla, 41012, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • FISABIO
    Valencia, 46020, Spain
  • Centro de Salud la Serreria II
    Valencia, 46022, Spain
  • Centro de Salud Nazaret
    Valencia, 46024, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Sep 2022, 21 months.

Results were first posted in Mar 2024, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Nov 27, 2020
StartActual
Nov 26, 2020
Primary completionActual
Sep 15, 2022
CompletionActual
Sep 15, 2022
Results first posted
Mar 25, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04645966
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 27, 2020
Start date
Nov 26, 2020
Primary completion
Sep 15, 2022
Completion
Sep 15, 2022
Results posted
Mar 25, 2024
Last update
Mar 25, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meningococcal pentavalent vaccine · 4CMenB vaccine

Start the discussion